RUNX1 and acute myeloid leukemia: We used retroviral overexpression of two AML fusion oncogenes (MLL-AF9 and AML1-ETO9a) that generate separate and disparate models of AML, are associated with a clinical range from good to poor prognosis, and markedly differ in their mechanisms of leukemic transformation.